# US 2026/0097040 A1 · Use of reboxetine to treat narcolepsy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097040 A1
- Document ID: US20260097040A1
- Status: Published application
- Kind: A1
- Application number: 19/417,205
- Filed: 2025-12-11
- Published: 2026-04-09
- Earliest claimed: 2019-12-03
- Assignees: Axsome Therapeutics, Inc.
- Applicants: Axsome Therapeutics, Inc.
- Inventors: Herriot Tabuteau
- Web page: https://patentgrep.com/patent/US20260097040A1

## CPC

- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61P 25/20: Hypnotics; Sedatives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.

## Claims

### Claim 1

A method of reducing daytime sleepiness, comprising administering about 8 mg to about 10 mg of reboxetine daily for at least two weeks to a human being in need thereof, wherein the human being is experiencing narcolepsy with cataplexy, wherein during the second week that reboxetine is administered, the human being experiences less daytime sleepiness than the week before the human being first received reboxetine, as determined by the human being's Epworth Sleepiness Scale scores.

### Claim 2 (depends on 1)

The method of claim 1, wherein the human being is selected for having experienced at least 7 cataplexy attacks in the week before the human being first received reboxetine.

### Claim 3 (depends on 1)

The method of claim 1, wherein reboxetine is administered once a day.

### Claim 4 (depends on 1)

The method of claim 1, wherein reboxetine is administered in a dosage form further containing a polymer.

### Claim 5 (depends on 1)

The method of claim 1, wherein reboxetine is administered in a dosage form further containing a binder.

### Claim 6 (depends on 1)

The method of claim 1, wherein reboxetine is administered in a dosage form further containing a lubricant.

### Claim 7 (depends on 1)

The method of claim 1, wherein reboxetine is administered in a dosage form further containing a diluent.

### Claim 8 (depends on 1)

The method of claim 1, wherein reboxetine is administered in a dosage form further containing a disintegrant.

### Claim 9 (depends on 1)

The method of claim 1, wherein 4 mg of the reboxetine is administered twice a day to the human being for a first week.

### Claim 10 (depends on 9)

The method of claim 9, wherein 4 mg of the reboxetine is administered to the human being in the morning and 4 mg of the reboxetine is administered to the human being in the afternoon for a second week.

### Claim 11 (depends on 1)

The method of claim 1, wherein 6 mg of the reboxetine is administered to the human being in the morning and 4 mg of the reboxetine is administered to the human being in the afternoon for a first week.

### Claim 12 (depends on 11)

The method of claim 11, wherein 6 mg of the reboxetine is administered to the human being in the morning and 4 mg of the reboxetine is administered to the human being in the afternoon for a second week.

### Claim 13 (depends on 1)

The method of claim 1, wherein 5 mg of the reboxetine is administered to the human being in the morning and 5 mg of the reboxetine is administered to the human being in the afternoon for a first week.

### Claim 14 (depends on 13)

The method of claim 13, wherein 5 mg of the reboxetine is administered to the human being in the morning and 5 mg of the reboxetine is administered to the human being in the afternoon for a second week.

### Claim 15 (depends on 1)

The method of claim 1, wherein the human being has a diagnosis of narcolepsy with cataplexy that meets International Classification of Sleep Disorders, Third Edition criteria.

### Claim 16 (depends on 1)

The method of claim 1, wherein the human being has an Epworth Sleepiness Scale score that is greater than 10 prior to receiving the reboxetine.
